Century Therapeutics, Inc.
IPSC
$2.21
$0.094.25%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | 1,556.51% | 4,121.12% | 5,489.03% | 8,286.79% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | 1,556.51% | 4,121.12% | 5,489.03% | 8,286.79% |
| Cost of Revenue | -21.94% | -10.80% | 5.17% | 14.96% | 21.01% |
| Gross Profit | -2,016.93% | 113.42% | 108.20% | 104.36% | 105.00% |
| SG&A Expenses | -13.19% | -12.69% | -7.96% | -5.26% | -3.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.91% | -11.25% | 1.84% | 9.59% | 14.25% |
| Operating Income | -299.53% | 88.32% | 82.29% | 77.62% | 76.84% |
| Income Before Tax | -435.06% | 92.27% | 81.11% | 83.66% | 84.82% |
| Income Tax Expenses | -103.80% | -103.80% | 307.96% | 796.06% | 165.58% |
| Earnings from Continuing Operations | -391.11% | 92.44% | 79.62% | 82.28% | 83.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -391.11% | 92.44% | 79.62% | 82.28% | 83.56% |
| EBIT | -299.53% | 88.32% | 82.29% | 77.62% | 76.84% |
| EBITDA | -559.06% | 97.88% | 91.16% | 86.33% | 86.03% |
| EPS Basic | -293.91% | 93.52% | 83.42% | 86.35% | 87.34% |
| Normalized Basic EPS | -408.92% | 94.42% | 90.09% | 87.89% | 88.37% |
| EPS Diluted | -287.96% | 93.26% | 82.96% | 85.94% | 87.09% |
| Normalized Diluted EPS | -407.04% | 94.36% | 90.04% | 87.84% | 88.32% |
| Average Basic Shares Outstanding | 34.07% | 10.02% | 19.04% | 29.77% | 40.35% |
| Average Diluted Shares Outstanding | 34.04% | 10.04% | 19.07% | 29.80% | 40.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |